PegIntron [peginterferon alfa-2b]/REBETOL [ribavirin] Combination Therapy Designated Drug Use Investigation -Investigation on the Safety and Efficacy of PegIntron and REBETOL Combination Therapy in Patients With Chronic Hepatitis C Excluding Those With 'IFN [interferon] Naive Low Viral Load and Genotype 1 and High Viral Load.

Trial Profile

PegIntron [peginterferon alfa-2b]/REBETOL [ribavirin] Combination Therapy Designated Drug Use Investigation -Investigation on the Safety and Efficacy of PegIntron and REBETOL Combination Therapy in Patients With Chronic Hepatitis C Excluding Those With 'IFN [interferon] Naive Low Viral Load and Genotype 1 and High Viral Load.

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Apr 2014

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Ribavirin (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms COMPLETED
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 28 Jan 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 20 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top